39 Firmen mit Ergebnissen für "efficacy com com com com com com com com com com com com"

University of Zurich

https://www.campus-schlieren.uzh.ch/en.html  

8952 Schlieren, Wagistrasse 12

The University of Zurich (UZH) is Switzerland’s largest university, with seven faculties and a current enrollment of over 26,000 students. More than 5,000 highly qualified members of the teaching staff, including some 580 professors, teach and conduct research at the 150 University institutes. In the field of life sciences, the University of Zurich is well known for its groundbreaking research in medicine, immunology, neuroscience, and structural biology. In the interest of serving the community, the University of Zurich promotes the transfer of research-based knowledge to private enterprise, and our spin-off ventures and business partnerships regularly lead to the creation of attractive jobs in innovative fields.

University of Zurich

Wagistrasse 12

8952 Schlieren

895 Ergebnisse für "efficacy com com com com com com com com com com com com" unter University of Zurich

UZH - URPP Dynamics of Healthy Aging - Dipl. rer. com. Susanne Nieke

... Susanne Nieke, Dipl. rer. com. Wissenschaftliche Mitarbeiterin ... UZH - URPP Dynamics of Healthy Aging - Dipl. rer. com. Susanne Nieke ... UZH - URPP Dynamics of Healthy Aging - Dipl. rer. com. Susanne Nieke Home Main navigation Search ... UZH - URPP Dynamics of Healthy Aging - Dipl. rer. com. Susanne Nieke ...

Mehr Ergebnisse

ETH Entrepreneurship

https://ethz.ch/en/industry/entrepreneurship.html  

8952 Schlieren, Wagistrasse 18


 entrepreneurship@ethz.ch

Excellence in entrepreneurship at ETH Zurich is driven by world-​class research and education. It gives rise to groundbreaking new ventures that consolidate Switzerland’s technological leadership. Are you an aspiring entrepreneur seeking to find solutions to global challenges and create a better future for humanity. Or are you just interested in the entrepreneurial ecosystem at ETH Zurich? Browse our websites to find out more or reach out to the Entrepreneurship group, if you have any questions. 

ETH Entrepreneurship

Wagistrasse 18

8952 Schlieren

Somagenetix

https://www.wysszurich.ch/projects/somagenetix  

8952 Schlieren, Wagistrasse 23

Gene therapy solutions for patients with severe inherited diseases.

Somagenetix

Wagistrasse 23

8952 Schlieren

Blutspende SRK Zürich

https://www.blutspendezuerich.ch/  

8952 Schlieren, Rütistrasse 19

 +41 58 272 52 52
 info@zhbsd.ch

The Zurich Blood Transfusion Service SRK (ZHBSD) is a nonprofit foundation and independent partner in the healthcare sector. It ensures the supply of blood and blood products to patients in the Zurich region. Our products are made exclusively from voluntary, unpaid blood donations. We offer our services at cost-covering prices and without government subsidies. Along with ten other regional blood donation services in Switzerland, we are a member of the Swiss Red Cross Blood Donation Service (BSD SRK AG).

Blutspende SRK Zürich

Rütistrasse 19

8952 Schlieren

80 Ergebnisse für "efficacy com com com com com com com com com com com com" unter Blutspende SRK Zürich

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

... Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine The new england journal of medicine n ... Pfizer, 401 N. Middletown Rd., Pearl River, NY 10965, or at judith . absalon@ pfizer . com. *A complete ... Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine ... Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine The new england journal of medicine n ... Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine ...

Clinical Impact of Amotosalen-UVA Pathogen Inactivated Platelets St...

... , et al. Comparison of transfusion efficacy of amotosalen-based pathogen-reduced platelet com- ponents ... efficacy and safety. T he Swiss Red Cross Blood Transfusion Services introduced universal treatment of all ... , et al. Comparison of transfusion efficacy of amotosalen-based pathogen-reduced platelet com- ponents ... efficacy and safety. T he Swiss Red Cross Blood Transfusion Services introduced universal treatment of all ...

Mehr Ergebnisse

Molecular Partners AG

http://www.molecularpartners.com  

8952 Schlieren, Wagistrasse 14

 +41 44 755 77 00

Molecular Partners AG is a clinical-stage biopharmaceutical company, located in Schlieren, Switzerland, that is developing a new class of therapies known as DARPin® therapies.

Molecular Partners AG

Wagistrasse 14

8952 Schlieren

31 Ergebnisse für "efficacy com com com com com com com com com com com com" unter Molecular Partners AG

Actavis confirms timeline for the start of phase III development of...

... ™, a product that inhibits both VEGF and PDGF, through preclinical and clinical development to com ... efficacy of abicipar and its potential to improve vision gains whilst reducing the number of treatment ... ™, a product that inhibits both VEGF and PDGF, through preclinical and clinical development to com ...

Shareholders of Molecular Partners AG approved all Board proposals ...

... also re-elected. The shareholders of Molecular Partners AG also approved the proposed respective com ... Partners AG also approved the proposed respective com-pensation amounts for the Board of Directors and the ...

Mehr Ergebnisse

University Hospital Zurich​, Research and Education Office

https://www.usz.ch/forschung/Seiten/default.aspx  

8091 Zürich, Rämistrasse 100

The University Hospital Zurich is one of Switzerland’s largest hospitals and a pioneering institution in the field of clinical research. In its 40 departments and institutes, it assembles and practices all medical disciplines and enjoys an excellent reputation for state-of-the-art medicine, professional and com- passionate patient care, and groundbreaking bench-to-bedside translational medical research.

University Hospital Zurich​, Research and Education Office

Rämistrasse 100

8091 Zürich

172 Ergebnisse für "efficacy com com com com com com com com com com com com" unter University Hospital Zurich​, Research and Education Office

untitled

... , Chair for Com- plementary and Inte- grative Medicine at the University of Zurich. D ow nl oa de d by ... randomized controlled trials providing information on the efficacy of a treatment (evidence from ideal study ... , Chair for Com- plementary and Inte- grative Medicine at the University of Zurich. D ow nl oa de d by ... randomized controlled trials providing information on the efficacy of a treatment (evidence from ideal study ...

Effect of High-Dosage Cholecalciferol and Extended Physiotherapy on...

... identified by com- paring the date and circumstances of each report from differ- ent ascertainment methods ... % (adjusted relative rate dif- ference,−25%; 95% CI, −44% to −1%; Table 2). In an efficacy analysis based on ... identified by com- paring the date and circumstances of each report from differ- ent ascertainment methods ... % (adjusted relative rate dif- ference,−25%; 95% CI, −44% to −1%; Table 2). In an efficacy analysis based on ...

Mehr Ergebnisse

Roche Glycart AG

https://www.roche.ch/en/sites/schlieren  

8952 Schlieren, Wagistrasse 10

 +41 43 215 10 00

The mission of the Roche Innovation Center Zurich (RICZ) is to be a leader in developing new generations of engineered antibody products with increased efficacy that address unmet clinical needs. The RICZ site is also the Center of Excellence in Cancer Immunotherapy within the Roche Group.

Roche Glycart AG

Wagistrasse 10

8952 Schlieren

556 Ergebnisse für "efficacy com com com com com com com com com com com com" unter Roche Glycart AG

Roche launches SARS-CoV-2 molecular test to aid in the public healt...

... possibly decreased therapeutic and vaccine efficacy.1-4     “Viruses naturally evolve over time. While most ... diminishing vaccine efficacy.4 Variant P.1, a close relative to B.1.351, has several defining mutations ... increased disease transmissibility, and possibly decreased therapeutic and vaccine efficacy. 1-4 ... evade the body’s immune response, possibly diminishing vaccine efficacy. 4 Variant P.1, a close relative ...

Roche launches SARS-CoV-2 variant test to help monitor emerging cor...

... disease transmissibility, and possibly decreased therapeutic and vaccine efficacy.1-4   Viruses naturally ... diminishing vaccine efficacy.4 Variant P.1, a close relative to B.1.351, has several defining mutations ... efficacy. 1-4   Viruses naturally evolve over time. While most mutations do not have a clinical impact ... evade the body’s immune response, possibly diminishing vaccine efficacy. 4  Variant P.1, a close ...

Mehr Ergebnisse

CSL Vifor

https://www.csl.com/we-are-csl/our-businesses-and-products/csl-vifor  

8952 Schlieren, Zürcherstrasse 39D

 +41 58 851 80 00

Pioneer in iron-based therapies, CSL Vifor is a global leader in iron deficiency and iron deficiency anaemia therapies, with a history dating back to 1872, when pharmacist Caspar Friedrich Hausmann opened a pharmacy in St. Gallen, Switzerland. Since then, we have proven our ability to identify and serve therapeutic areas and patients with significant unmet medical need. Building on our heritage and expertise in iron deficiency therapy, and together with our joint company Vifor Fresenius Medical Care Renal Pharma, today we have a strong and rapidly growing presence in nephrology, and we are committed to launching the next generation of therapies to truly address the full spectrum of kidney disease.

CSL Vifor

Zürcherstrasse 39D

8952 Schlieren

24 Ergebnisse für "efficacy com com com com com com com com com com com com" unter CSL Vifor

CSL Seqirus Begins Shipping Portfolio of Innovative Influenza Vacci...

... geographic area and the potential for confounding and bias. FLUCELVAX QUADRIVALENT immunogenicity, efficacy ... additional information on influenza vaccine options for the upcoming flu season, visit flu360. com. About ... bias. FLUCELVAX QUADRIVALENT immunogenicity, efficacy and safety are supported by randomized clinical ... influenza vaccine options for the upcoming flu season, visit flu360. com. About Seasonal Influenza Influenza ...

Current Clinical Trials | CSL

... . Dermatomyositis (DM) IgPro20_3007 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in ... Dose Regimens in Pediatric CIDP Long-term Safety and Efficacy of CSL312 (Garadacimab) in the ... to learn more) Dermatomyositis (DM) IgPro20_3007 A Study to Evaluate the Efficacy, Safety, and ... Angioedema (HAE) CSL312_3002 Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic ...

Mehr Ergebnisse

Zentrum für Kardiovaskuläre Genetik und Gendiagnostik c/o Stiftung für Menschen mit seltenen Krankheiten

http://www.genetikzentrum.ch/  

8952 Schlieren, Wagistrasse 25

 +41 43 433 86 86
 sekretariat@genetikzentrum.ch

Das Zentrum für Kardiovaskuläre Genetik und Gendiagnostik ist schweizweit das erste und einzige Zentrum, welches auf die molekulare Gendiagnostik und die Erforschung genetisch bedingter Aortenkrankheiten und deren klinische Konsequenzen, wie Aneurysmen und Dissektionen, spezialisiert ist.

Zentrum für Kardiovaskuläre Genetik und Gendiagnostik c/o Stiftung für Menschen mit seltenen Krankheiten

Wagistrasse 25

8952 Schlieren

2 Ergebnisse für "efficacy com com com com com com com com com com com com" unter Zentrum für Kardiovaskuläre Genetik und Gendiagnostik c/o Stiftung für Menschen mit seltenen Krankheiten

Recommendations for reporting of secondary findings in clinical exo...

... ., penetrance); efficacy of specific intervention(s); and overall strength of the current knowledge base about ... nomination form to collect all relevant informa- tion, SFWG members and colleagues were requested to com ... ., penetrance); efficacy of specific intervention(s); and overall strength of the current knowledge base about ... nomination form to collect all relevant informa- tion, SFWG members and colleagues were requested to com ...

... regions. Materials and Methods: We com- pared whole exome sequencing (WES, SureSelect Human All Exon v5 ... regions. Materials and Methods: We com- pared whole exome sequencing (WES, SureSelect Human All Exon v5 ...

CUTISS AG

http://cutiss.swiss  

8952 Schlieren, Grabenstrasse 11

 +41 44 244 36 60
 info@cutiss.swiss

After more than 15 years of research (Tissue Biology Research Unit, University Children’s Hospital Zurich), CUTISS AG can now bio-engineer large quantities of individually customized human skin grafts, denovoSkin™, starting off from a very small piece of healthy patient’s skin. Because of its intrinsic characteristics, denovoSkin™ is expected to result in a minimally scarring outcome after transplantation. denovoSkin™ received a Swissmedic, EMA and FDA Orphan drug designation for the treatment of burns.

CUTISS AG

Grabenstrasse 11

8952 Schlieren

254 Ergebnisse für "efficacy com com com com com com com com com com com com" unter CUTISS AG

Long-Term Outcomes of a Cultured Autologous Dermo-Epidermal Skin Su...

... , randomized, phase II clinical trial is currently ongoing to further evaluate the safety and efficacy of this ... , keratinocytes are seeded onto the surface of the graft to form the epidermal com- partment. After additional ... , randomized, phase II clinical trial is currently ongoing to further evaluate the safety and efficacy of this ... , keratinocytes are seeded onto the surface of the graft to form the epidermal com- partment. After additional ...

... generation skin grafts. Zurich, Switzerland, June 20th 2018 – CUTISS AG, a biotech com- pany spin-off of the ... generation skin grafts. Zurich, Switzerland, June 20th 2018 – CUTISS AG, a biotech com- pany spin-off of the ...

Mehr Ergebnisse

Mehr Firmen

Nach oben